LLY
ELI LILLY & Co
NYSE · Healthcare · Drug Manufacturers - General · US
$1,250.98
−0.48%Sep 29, 2026, 13:30 UTC
Republican Ron Schutz, candidate for Minnesota attorney general, disclosed a stock portfolio of more than $10,000 in each of 174 companies worth at least $1.74 million, creating potential conflicts of interest with corporations the office litigates.
Source:Sep 28, 2026, 17:45 UTC
Eli Lilly will present Phase 2 results for eloraTZP, a combination of eloralintide and tirzepatide, at EASD 2026 in Milan on Sept. 30, 2026.
Source:Sep 28, 2026, 17:45 UTC
Eli Lilly will present Phase 3 results for its experimental once-weekly injection retatrutide at the EASD 2026 symposium in Milan on Sept. 30, 2026.
Source:Sep 25, 2026, 11:30 UTC
Federal cases alleging that GLP-1 medicines from Novo Nordisk and Eli Lilly caused non-arteritic anterior ischaemic optic neuropathy (NAION) were consolidated into a multidistrict litigation in Pennsylvania, with 216 actions pending as of September 1, 2026.
Source:Sep 25, 2026, 11:03 UTC
A jury awarded Nektar Therapeutics $90 million plus interest in its case against Eli Lilly.
Source:Sep 25, 2026, 11:02 UTC
A jury found Eli Lilly liable for breaching the implied covenant of good faith in a licensing agreement, according to regulatory filings.
Source:Sep 25, 2026, 10:30 UTC
Katwijk City Council signaled majority support for granting Eli Lilly a permit to build a multi-billion euro pharmaceutical factory in Katwijk, Netherlands, with a final council vote scheduled for October 1.
Source:Sep 24, 2026, 16:15 UTC
The FDA warned Houston-based Empower Pharmacy that it violated federal law by mass-copying patented GLP-1 weight-loss drugs in inordinate amounts, giving the pharmacy an opportunity to comply.
Source:Sep 24, 2026, 16:00 UTC
US Senator Todd Young, chairman of the National Security Commission on Emerging Biotechnology, called for creating a White House-level federal biotech leader and for reducing US strategic dependence on Chinese biopharmaceutical innovation over time.
Source:Sep 24, 2026, 11:45 UTC
Novo Nordisk shares fell nearly 8% after its capital markets day outlook disappointed investors, while Eli Lilly shares rose more than 1% the same day.
Source:Sep 24, 2026, 11:27 UTC
The US Food and Drug Administration approved Eli Lilly's once-weekly basal insulin Onswik for adults with type 2 diabetes.
Sep 24, 2026, 06:30 UTC
Novo Nordisk reduced its global workforce by around 13,000 over the past year, leaving about 67,000 employees, as part of a restructuring to cut costs and redirect resources to research and development.
Source:Sep 18, 2026, 19:16 UTC
The US FDA approved Eli Lilly's drug combination to treat adults with advanced breast cancer that has spread to other parts of the body.
Source:Sep 14, 2026, 20:37 UTC
Eli Lilly said its oral weight-loss drug Foundayo has captured more than 30% of new US patients on oral obesity treatments, narrowing Novo Nordisk's early lead with its Wegovy pill.
Source:Aug 4, 2026, 12:45 UTC
Amplia Therapeutics entered into a Clinical Trial Collaboration and Supply Agreement with Eli Lilly to evaluate narmafotinib combined with olomorasib in non-small cell lung cancer.
Jul 30, 2026, 12:58 UTC
Eli Lilly and Resilience jointly invest $750 million to expand pharmaceutical manufacturing capacity in the United States.
Source:Jul 10, 2026, 16:15 UTC
The U.S. House Select Committee on the Chinese Communist Party launched a bipartisan investigation into five major American pharmaceutical companies over clinical trials conducted in China, including at hospitals linked to the People's Liberation Army and in Xinjiang province, sending letters demanding records by July 17.
Jul 8, 2026, 07:55 UTC
Eli Lilly acquired Centessa Pharmaceuticals for $7.8 billion.
Source:Jun 30, 2026, 08:30 UTC
The Trump administration negotiated a monthly $245 price for GLP-1 drugs in Medicare and Medicaid with Eli Lilly and Novo Nordisk, contingent on private Medicare insurers covering the drugs for all uses with a $50 copay.
Source:Jun 30, 2026, 04:00 UTC
Innovent Biologics and Eli Lilly entered into a distribution and promotion agreement for Verzenios (abemaciclib) in mainland China.
Jun 29, 2026, 18:53 UTC
The FDA selected Eli Lilly and Regeneron among the first seven companies for its PreCheck Pilot Program to speed review of new manufacturing facilities.
Source:Jun 26, 2026, 11:16 UTC
Eli Lilly's Jaypirca (pirtobrutinib) received a positive opinion from the CHMP recommending approval in the European Union for adults with chronic lymphocytic leukemia across all lines of therapy.
Jun 26, 2026, 08:23 UTC
Eli Lilly launched The Memory Radio Station, a travelling public radio station and exhibition, across Europe to raise awareness of Alzheimer's disease early symptoms.
Jun 25, 2026, 05:00 UTC
Eli Lilly launched its own data center with 1,016 advanced Blackwell computer chips from Nvidia as part of a push into AI for drug discovery.
Source:Jun 24, 2026, 20:01 UTC
Eli Lilly invested $40 million in Absci for equity, leading a $50 million funding round.
Source:Jun 24, 2026, 01:38 UTC
Abbisko Therapeutics entered into a strategic research collaboration and license agreement with Eli Lilly.
Source:Jun 23, 2026, 13:00 UTC
NVIDIA announced the BioNeMo Agent Toolkit, a set of tools for agents to accelerate scientific discovery.
Jun 23, 2026, 04:55 UTC
Eli Lilly plans to launch a data center with 1,016 Blackwell chips in 2025.
Source:Jun 19, 2026, 08:07 UTC
Amgen India appointed Anjali Rao as executive director of human resources.
Source:
Page 1Next →